HVEM/TNFRSF14 Antibody (2742C) [Alexa Fluor® 647]

• Reactivity: Hu
• Applications: IHC
• Clone: 2742C
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Alexa Fluor 647

HVEM/TNFRSF14 Antibody (2742C) [Alexa Fluor® 647] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Human embryonic kidney cell HEK293-derived human HVEM/TNFRSF14
  Pro37-Val202
  Accession # Q92956
• Specificity: Detects human HVEM/TNFRSF14 in direct ELISAs.
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for HVEM/TNFRSF14 Antibody (2742C) [Alexa Fluor® 647]

• ATAR
• CD270 antigen
• CD270
• CD40-like protein
• Herpes virus entry mediator A
• Herpesvirus entry mediator A
• HveA
• HVEM
• HVEMTR2HVEAATAR
• LIGHTR
• TNFRSF14
• tumor necrosis factor receptor superfamily member 14
• tumor necrosis factor receptor superfamily, member 14 (herpesvirus entrymediator)
• Tumor necrosis factor receptor-like 2
• tumor necrosis factor receptor-like gene2

Background

Herpesvirus entry mediator (HVEM), also referred to as TR2 (TNF receptor-like molecule) and ATAR (another TRAF-associated receptor), is a type I membrane protein belonging to the TNF/NGF receptor superfamily. In the TNF superfamily nomenclature, HVEM is referred to as TNFRSF14. Human HVEM cDNA encodes a 283 amino acid (aa) protein with a probable 36 aa signal peptide, a 166 aa extracellular domain, a 23 aa transmembrane region and a 58 aa cytoplasmic region. The extracellular domain of HVEM contains several cysteine-rich repeats characteristic of TNF receptor superfamily members. The short cytoplasmic region lacks a death domain present in some TNF receptor family members, but contains a TRAF (TNF receptor-associated factor) interaction domain. HVEM expression has been detected in peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells. The extracellular domain of HVEM has been shown to interact directly with the herpes simplex virus envelope glycoprotein D. Two TNF superfamily ligands, including the secreted TNF‑ beta  (lymphotoxin  alpha ) and the membrane protein LIGHT (lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes), have been shown to be the cellular ligands for HVEM. Besides HVEM, LIGHT can also interact with LT beta R, the receptor for lymphotoxin alpha beta heterotrimer.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q92956()